Novel antifungal agents in clinical trials [version 2; peer review: 2 approved]

Invasive fungal diseases due to resistant yeasts and molds are an important and increasing public health threat, likely due to a growing population of immunosuppressed hosts, increases in antifungal resistance, and improvements in laboratory diagnostics.  The significant morbidity and mortality asso...

Full description

Saved in:
Bibliographic Details
Published in:F1000 research Vol. 10; p. 507
Main Authors: Jacobs, Samantha E, Zagaliotis, Panagiotis, Walsh, Thomas J
Format: Journal Article
Language:English
Published: England Faculty of 1000 Ltd 2022
F1000 Research Limited
F1000 Research Ltd
Subjects:
Amphotericin B
Antifungal Agents
Antifungal Agents - pharmacology
Antifungal Agents - therapeutic use
Biosynthesis
Clinical trials
Drug dosages
Drug interactions
Drug Resistance, Fungal
eng
Enzymes
Fungi
Immunocompromised Host
Meningitis
Morbidity
Neutropenia
novel treatments
Pathogens
Pharmacodynamics
pharmacokinetic and pharmacodynamic
Pharmacokinetics
Proteins
Public health
Review
Antifungal Agents
clinical trials
pharmacokinetic and pharmacodynamic
novel treatments
ISSN:2046-1402, 2046-1402
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Invasive fungal diseases due to resistant yeasts and molds are an important and increasing public health threat, likely due to a growing population of immunosuppressed hosts, increases in antifungal resistance, and improvements in laboratory diagnostics.  The significant morbidity and mortality associated with these pathogens bespeaks the urgent need for novel safe and effective therapeutics.  This review highlights promising investigational antifungal agents in clinical phases of development: fosmanogepix, ibrexafungerp, rezafungin, encochleated amphotericin B, oteseconazole (VT-1161), VT-1598, PC945, and olorofim.  We discuss three first-in-class members of three novel antifungal classes, as well as new agents within existing antifungal classes with improved safety and tolerability profiles due to enhanced pharmacokinetic and pharmacodynamic properties.
Bibliography:new_version
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
Competing interests: TJW has received grants for experimental and clinical antimicrobial pharmacology and therapeutics to his institution from Allergan, Amplyx, Astellas, Lediant, Medicines Company, Merck, Scynexis, Tetraphase, and Viosera; and has served as consultant to Amplyx, Astellas, Allergan, ContraFect, Gilead, Lediant, Medicines Company, Merck, Methylgene, Pfizer, and Scynexis. SEJ and PZ declare no competing interests.
ISSN:2046-1402
2046-1402
DOI:10.12688/f1000research.28327.2